

List of Figures

Figure 1	Pancreas topography (A) and anatomy of the Langerhans islets (B)	1
Figure 2a	Representation of signalling and transcription factors involved in endocrine pancreatic development	3
Figure 2b	Representation of endocrine and exocrine pancreatic development	4
Figure 3	Schematic representation of insulin synthesis	6
Figure 4	Mechanisms in insulin release from β -cells	7
Figure 5	Insulin signaling in β -cells of the endocrine pancreas	8
Figure 6	Intra-islet interactions between A (α -), B (β -) and D (δ -) cells of the endocrine pancreas	12
Figure 7	Structure of SST receptor showing intracellular and extracellular domains	13
Figure 8	Structure of SSTRs nonpeptide agonists where L-796,778, L-779,976, L-797,591, L-803,087, and L-817,818 are selective agonists for SSTR1, SSTR2, SSTR3, SSTR4 and SSTR5 respectively	18
Figure 9	Expression of SSTRs 1-5 in A and B- cells of the human endocrine pancreas (hsstr = Human SSTR)	22
Figure 10	Schematic representation of retinal neovascularization of an eye in nontransgenic mouse	24
Figure 11	Schematic representation of the function of SSTR2 in T2DM	27
Figure 12	Schematic representations of the steps involved in the procedure for the preparation of isolated human pancreatic islets	41

Figure 13	Schematic representation of perfusion of mice pancreas	49
Figure 14	Murine pancreas in situ injected with a solution containing liberase RI	49
Figure 15A	Identification of SSTRs expression by RT-PCR in INS-1 and InR1-G9 cells. Amplification of SSTR2 and SSTR3 in the given cell models by using rat primers. No signal for SST1, 4 and 5. Positive controls for RT-PCR: rat brain (RB) for all SSTRs	62
Figure 15B	Identification of SSTR2 by immunofluorescence. (i) represents INS-1 cells, (ii) is the positive control for SSTR2 (SSTR2 transfected RIN cells), and (iii) is the negative control(CHO cells)	62
Figure 16	Effect of SST-14, SSTR2 and SSTR3-selective agonists (10^{-6} M – 10^{-12} M) on forskolin-induced intracellular cAMP accumulation in INS-1 cells. (n=4)	63
Figure 17	Effect of SST-14 and SSTR2 selective agonist (10^{-6} M – 10^{-12} M) on 20 mM glucose + 10 nM exendin-4 (GLP-1 agonist) induced insulin secretion in INS-1 cells. Cells were incubated for 1 h with SST-14 and SSTR2 selective agonist. The concentration of released insulin in the buffer was determined. Basal secretion was determined at 3.3 mM glucose (n = 4)	64
Figure 18	Consequence of the of R-type Ca^{2+} channel blockade on SST-14 and SSTR2 and SSTR3 selective agonists induced inhibition of 20 mM glucose + 10 nM exendin-4 (GLP-1 agonist) stimulated insulin secretion from INS-1 cells. INS-1 cells were incubated for 1 h with SST-14, SSTR2, and SSTR3 selective agonists (at the indicated concentrations). The concentration of secreted insulin in the medium was determined by ELISA. The data are expressed in percent of maximal secretion, defined as the amount of secreted insulin in the presence of 20 mM D-glucose + 10 nM exendin-4, only. Basal insulin secretion was determined at 3.3 mM glucose. n= 4, *p<0.05, **p<0.01, ***p<0.001 vs. stimulated secretion (1 h-secretion at 20 mM glucose + 10 nM exendin-4). A: The inhibitory effect of SST-14, SSTR2 and SSTR3 selective agonists on 20 mM glucose + 10 nM exendin-4 induced insulin secretion. The weakest inhibition of insulin secretion was observed in the presence of SSTR3 selective agonist (right panel). B: The inhibitory effect of SST-14, SSTR2 and SSTR3 selective agonists on 20 mM glucose + 10 nM exendin-4 induced insulin secretion was	

reduced by the R-type Ca^{2+} channel blocker SNX-482 (at the indicated concentrations). The maximal inhibition by SST-14, SSTR2 and SSTR3 selective agonist effect was set to 100 %. The weakest reduction of the inhibition of insulin by SNX-482 was observed in SSTR3-treated cells (right panel) 66

Figure 19 Effect of SST-14 and SSTR2 selective agonist on PI3K dependent pathway by Western blot. Decrease of PDK1 and Akt phosphorylation levels, no effect on total PDK1 and Akt protein in INS-1 cells 68

Figure 20 Identification of SSTR2 by immunofluorescence. (i) represents InR1-G9 cells, (ii) represents HEK 293 (positive control) for SSTR2 69

Figure 21 Effect of SST-14 and SSTR2-selective agonists (10^{-6} M – 10^{-12} M) on forskolin-induced intracellular cAMP accumulation in InR1-G9 cells. (n = 4) 70

Figure 22 Effect of SST-14 and SSTR2 (10^{-6} M – 10^{-12} M) selective agonist on glucagon secretion from InR1-G9 cells at 5mM glucose. Cells were incubated in KRB buffer containing 20 mM L-arginine+ 100 μ M IBMX for 1 h with SST-14 and SSTR2 selective agonist. The concentration of released glucagon in the buffer was determined. The data are expressed in percent of maximal secretion (\pm SEM), defined as secreted glucagon in the presence of 20 mM L-arginine+ 100 μ M IBMX. (n = 4) 71

Figure 23 Schematic representation of enzymes and pathways involved in hepatic glycogen control in SSTR2^{-/-} mice 98

Figure 24 Flow chart showing steps and enzymes involved in gluconeogenesis pathway 100

Figure 25 Schematic representation of intracellular signaling followed by SSTR2 in INS-1 cells 102

Figure 26 Schematic representation of novel mechanism of glucose –dependent inhibition of glucagon secretion and potential therapeutical application 104